Nicox S.A. completed the pricing of an offering a reserved capital increase of ordinary shares of the Company to a specific category of investors. The gross proceeds of the financing are approximately €18 million, for a total of 2,064,000 million new shares. Needham acted as lead placement agent for this transaction. The net proceeds from the sale of the Units will be used by Nicox S.A. for clinical development of pipeline candidates (NCX 4251 in blepharitis and NCX 470 in glaucoma), working capital and general corporate purposes.
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.